Drug intelligence / Profile preview

HKB99

Development stage: Preclinical
Lead developer: Shanghai Jiao Tong University
Modality: Small Molecules
Administration: Intraperitoneal

Overview

HKB99 is a small molecule inhibitor originally identified as targeting phosphoglycerate mutase 1 (PGAM1). Recent research indicates that it also acts as a microtubule-disrupting agent by binding to tubulin alpha-1B (TUBA1B), thereby inhibiting tubulin polymerization and disrupting bipolar spindle formation. In the context of HER2-positive breast cancer, HKB99 has been shown to synergize with trastuzumab to overcome resistance by inducing mitotic catastrophe, characterized by M-phase arrest and chromosomal missegregation. It is being investigated for its potential to enhance the efficacy of anti-HER2 therapies.

Targets

PGAM1 (Phosphoglycerate mutase family member 4)

Beyond the preview

Go deeper on HKB99.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HKB99.

Explore the full profile